Table. 6.

Ongoing clinical trials of immunotherapy for cancer in transplant patients

Organ Study title Registration Cancer Interventions Phase Start date
Kidney Nivolumab in renal transplant recipients with poor prognosis cancers - a safety study [93] ANZCTR Registration No. ACTRN12617000741381 cSCC, head & neck SCC, melanoma, MCC, NSCLC, urothelial cancer, colorectal cancer, breast cancer, etc. Nivolumab I May 22, 2017
Kidney Tacrolimus, nivolumab, and ipilimumab in treating kidney transplant recipients with selected unresectable or metastatic cancers [94] Identifier NCT03816332 Melanoma, MCC, BCC, cSCC Tacrolimus, nivolumab, ipilimumab I Feb 1, 2019
Kidney Cemiplimab in AlloSCT/SOT recipients with cSCC (CONTRAC) [94] Identifier NCT04339062 cSCC Cemiplimab, everolimus, sirolimus, prednisone I/II Jul 15, 2020
Liver Safety and efficacy of PD-1 inhibitors in patients with liver transplant [94] Identifier NCT03966209 HCC JS001 (PD-1 inhibitor) I May 1, 2019
Liver Atezolizumab and bevacizumab before surgery for the treatment of resectable liver cancer Identifier NCT04721132 HCC Atezolizumab, bevacizumab II Feb 10, 2021

ANZCTR, Australian New Zealand Clinical Trials Registry; cSCC, cutaneous squamous cell carcinoma; MCC, Merkel cell carcinoma; NSCLC, non-small cell lung cancer; BCC, basal cell carcinoma; AlloSCT, allogeneic stem cell transplant; SOT, solid-organ transplant; PD-1, programmed cell death protein 1; HCC, hepatocellular carcinoma recurrence.

Korean J Transplant 2022;36:82~98
© Korean J Transplant